BBOT director granted 63,350 stock options

BridgeBio Oncology Therapeutics, Inc. director Peter F. Lebowitz received a grant of stock options covering 63,350 shares of common stock.

Rhea-AI Filing Summary

BridgeBio Oncology Therapeutics, Inc. director Peter F. Lebowitz received a grant of stock options covering 63,350 shares of common stock. The options have an exercise price of $8.72 per share and expire on March 23, 2036.

According to the vesting terms, 1/36th of the options vest in substantially equal monthly installments on each monthly anniversary of March 24, 2026, so long as he continues to provide service to the company. Following this grant, he holds 63,350 derivative securities directly.

Insider Trade Summary

Grant/Award: 63,350 shares

Grant/Award 1 txn

Insider Lebowitz Peter F

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	63,350	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 63,350 contracts (Direct)

Footnotes (1)

1. F1. 1/36th of the shares subject to such option vest and become exercisable in substantially equal monthly installments on each monthly anniversary of March 24, 2026, subject to the Reporting Person's continuous service to the Issuer on each such date.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Peter F. Lebowitz report in his Form 4 for BridgeBio Oncology Therapeutics (BBOT)?

Peter F. Lebowitz reported receiving a grant of stock options for 63,350 shares of BridgeBio Oncology Therapeutics common stock. These options were awarded as a compensation-related acquisition and are not an open-market purchase or sale of existing shares.

What are the key terms of the 63,350 stock options granted to the BBOT director?

The options cover 63,350 shares of common stock at an exercise price of $8.72 per share and expire on March 23, 2036. They represent a right to buy shares in the future rather than an immediate share purchase.

How do the stock options granted to the BBOT director vest over time?

Vesting begins on March 24, 2026, with 1/36th of the options vesting in substantially equal monthly installments. Continued service to BridgeBio Oncology Therapeutics is required on each vesting date for additional portions of the grant to become exercisable.

Is the Form 4 for BBOT a sign of insider buying or selling on the open market?

No, this Form 4 reflects a grant of stock options as compensation, coded as a grant or award acquisition. It does not show any open-market buying or selling of BBOT common shares by the director on the transaction date disclosed.

How many derivative securities does the BBOT director hold after this option grant?

After this transaction, the director is reported as holding 63,350 derivative securities directly. These reflect the newly granted stock options tied to the company’s common stock, rather than already-owned common shares acquired on the market.

What is the expiration date of the BBOT director’s newly granted stock options?

The stock options granted to the director expire on March 23, 2036. If they are not exercised by that expiration date, the right to purchase the underlying 63,350 shares of common stock at the set exercise price will lapse.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/26/2026 - 05:14 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Lebowitz Peter F

(Last) (First) (Middle)

BRIDGEBIO ONCOLOGY THERAPEUTICS, INC.

256 EAST GRAND AVENUE, SUITE 104

(Street)

SOUTH SAN FRANCISCO CALIFORNIA 94080

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
BridgeBio Oncology Therapeutics, Inc. [ BBOT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/24/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$8.72	03/24/2026		A		63,350		(1)	03/23/2036	Common Stock	63,350	$0	63,350	D

Explanation of Responses:

1. 1/36th of the shares subject to such option vest and become exercisable in substantially equal monthly installments on each monthly anniversary of March 24, 2026, subject to the Reporting Person's continuous service to the Issuer on each such date.

	/s/ Aaron Chan, Attorney-in-Fact	03/26/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)